Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Lung inflammatory environments differentially alter mesenchymal stromal cell behavior

2019; American Physical Society; Volume: 317; Issue: 6 Linguagem: Inglês

10.1152/ajplung.00263.2019

1522-1504

Soraia C. Abreu, Sara Rolandsson Enes, Jacob Dearborn, Meagan Goodwin, Amy L. Coffey, Zachary D. Borg, Claúdia C. dos Santos, Matthew J. Wargo, Fernanda F. Cruz, Roberto Loi, Michael DeSarno, Takamuru Ashikaga, Mariana A. Antunes, Patrícia R. M. Rocco, Kathleen D. Liu, Jae Woo Lee, Michael A. Matthay, David H. McKenna, Daniel J. Weiss,

Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Mesenchymal stromal (stem) cells (MSCs) are increasingly demonstrated to ameliorate experimentally induced lung injuries through disease-specific anti-inflammatory actions, thus suggesting that different in vivo inflammatory environments can influence MSC actions. To determine the effects of different representative inflammatory lung conditions, human bone marrow-derived MSCs (hMSCs) were exposed to in vitro culture conditions from bronchoalveolar lavage fluid (BALF) samples obtained from patients with either the acute respiratory distress syndrome (ARDS) or with other lung diseases including acute respiratory exacerbations of cystic fibrosis (CF) (non-ARDS). hMSCs were subsequently assessed for time- and BALF concentration-dependent effects on mRNA expression of selected pro- and anti-inflammatory mediators, and for overall patterns of gene and mRNA expression. Both common and disease-specific patterns were observed in gene expression of different hMSC mediators, notably interleukin (IL)-6. Conditioned media obtained from non-ARDS BALF-exposed hMSCs was more effective in promoting an anti-inflammatory phenotype in monocytes than was conditioned media from ARDS BALF-exposed hMSCs. Neutralizing IL-6 in the conditioned media promoted generation of anti-inflammatory monocyte phenotype. This proof of concept study suggest that different lung inflammatory environments potentially can alter hMSC behaviors. Further identification of these interactions and the driving mechanisms may influence clinical use of MSCs for treating lung diseases.